NEW YORK, May 02, 2016 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today announced that David M. Brown, MD, Clinical Professor of Ophthalmology at Baylor College of Medicine, vice-chair for research at the Blanton Eye Institute, Houston Methodist Hospital, and partner at Retina Consultants of Houston, has been appointed to serve as the chair of the Steering Committee for the Phase 3 clinical program of squalamine lactate ophthalmic solution, 0.2% (“Squalamine,” also known as OHR-102) in wet-AMD. The steering committee will support the Phase 3 clinical development program, enhance the interactions with clinical investigators, and help to ensure the timely achievement of study milestones.
“I am excited to be playing such a key role in this important Phase 3 clinical program,” said Dr. Brown. “A topical medication with the potential to improve vision outcomes would be a tremendous advance in the treatment of patients with wet-AMD. I look forward to working with the team at Ohr in our mutual fight against blinding eye diseases.”
“Dr. Brown’s vast experience as a retinal specialist, investigator, clinical trial advisor and key opinion leader will be of great value to the Squalamine program and provide critical guidance to help advance this drug candidate through this key phase of its development as a potential topical therapy for wet-AMD in combination with Lucentis®,” said Jason S. Slakter, MD, Chief Executive Officer of Ohr Pharmaceutical. “The team at Ohr looks forward to working with David on this very exciting program.”
Dr. Brown is a world renowned thought leader on the research and treatments of age related macular degeneration (AMD), diabetic retinopathy, and retinal vein occlusion. His surgical interests are focused on macular surgery and the development of subretinal gene therapy techniques. Dr. Brown is an elected member of the Macula Society and the Retina Society and he serves on the board of directors of the American Society of Retina Specialists (ASRS). Dr. Brown’s major honors include the AAO Honor Award (2000), ASRS Honor Award (2008), ASRS Senior Honor Award (2010), AAO Senior Achievement Award (2014), and continuous election as one of the “Best Doctors in America” 2007-2015 and “Texas Super Docs” 2009-2015. He has written and published over 250 scientific papers, national meeting presentations and abstracts including many of the primary papers establishing the current standards of care for AMD, retinal vein occlusion, and diabetic retinopathy.
About Ohr Pharmaceutical, Inc.
Ohr Pharmaceutical, Inc. (Nasdaq:OHRP) is an ophthalmology research and development company. The company's lead product, squalamine lactate ophthalmic solution, 0.2% (“Squalamine,” also known as OHR-102), is currently being studied using an eye drop formulation in clinical trials for back-of-the-eye diseases, including the wet form of age-related macular degeneration, retinal vein occlusion, and proliferative diabetic retinopathy. In addition, Ohr has a sustained release micro fabricated micro-particle ocular drug delivery platform with several preclinical drug product candidates in development for glaucoma, steroid-induced glaucoma, ocular allergies, and protein drug delivery. Additional information on the company may be found at www.ohrpharmaceutical.com.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:
This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made only as the date thereof, and we undertake no obligation to update or revise the forward-looking statement whether as a result of new information, future events or otherwise. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the future success of our scientific studies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments, the financial resources available to us, and general economic conditions. Shareholders and prospective investors are cautioned that no assurance of the efficacy of pharmaceutical products can be claimed or assured until final testing; and no assurance or warranty can be made that the FDA will approve final testing or marketing of any pharmaceutical product. Our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q discuss some of the important risk factors that may affect our business, results of operations and financial condition.
Lucentis® is a registered trademark of Genentech, Inc.
Source:Ohr Pharmaceutical, Inc.